A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2020-10-06

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or refractory Medulloblastoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT00186875

Acute Lymphoblastic Leukemia Lymphoma, Lymphoblastic

COMPLETED PHASE2

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

NCT01962103

Neuroblastoma Rhabdomyosarcoma Ewing's Sarcoma +20 more

COMPLETED PHASE1/PHASE2

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT02303821

Acute Lymphoblastic Leukemia (ALL)

COMPLETED PHASE1

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

NCT05535166

Medulloblastoma

RECRUITING PHASE2

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

NCT00187122

Lymphoblastic Lymphoma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The maximum tolerated dose of TB-403 will be determined in pediatric subjects with relapsed or refractory Medulloblastoma (MB) and as well Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

bi-weekly intravenous doses of TB-403 20mg/kg

Intervention Type DRUG

TB-403 50mg/kg

bi-weekly intravenous doses of TB-403 50mg/kg

Intervention Type DRUG

TB-403 100mg/kg

bi-weekly intravenous doses of TB-403 100mg/kg

Intervention Type DRUG

TB-403 175mg/kg

bi-weekly intravenous doses of TB-403 175mg/kg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Provide written informed consent (Subject or legal representative)
2. Be \> 6 months and \< 18 years of age. For each dose cohort, the first 3 subjects must be at least 2 years of age
3. Have a histologically-confirmed diagnosis of MB, NB, ES, or ARMS
4. Have documented relapse or refractoriness after standard-of-care therapy
5. Have undergone magnetic resonance imaging (MRI) for MB (brain \[all cohorts\] and spinal cord \[cohort 4 only\], a computerized tomography (CT) / metaiodobenzylguanidine (MIBG) scan for NB, and CT / magnetic resonance imaging (MRI) for ES or ARMS within 1 month prior to first dose of study treatment
6. Have a Lansky score ≥ 40 for subjects up to 16 years of age or a Karnofsky score ≥ 40 for subjects 16 years of age to \< 18 years
7. Have adequate organ function, defined as:

* Peripheral absolute neutrophil count ≥ 1.5 × 10\^9/L
* Platelet count ≥ 100 × 10\^9/L (transfusion to reach this level is permitted)
* Hemoglobin ≥ 8mg/dL (transfusion to reach this level is permitted)
* International normalized ratio (INR) \< 1.5; partial thromboplastin time (PTT) \< 1.5 upper limit of normal (ULN)
* Creatinine clearance \> 50mL/min/1.73m2 or serum creatinine ≤ specified maximum values based on age, as described below:
* 6 months to 3 years of age: serum creatinine ≤ 0.4mg/dL
* 3 to 13 years of age: serum creatinine ≤ 0.7mg/dL
* \> 13 years of age: serum creatinine ≤ 1mg/dL
* Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) \< 2.5 × ULN; serum bilirubin \< 1.5 × ULN
8. Have no symptoms of cranial hypertension or convulsions within 14 days before Cycle 1 Day 1 (anti-epileptic drugs and corticoids are allowed to control any preexisting symptoms)
9. If female of child bearing potential, must not be lactating and must have a negative pregnancy test (blood or urine, at the discretion of the investigator) prior to enrollment and use effective contraception during study participation. Women should continue effective contraception for 3 months following last dose of TB-403.
10. If a sexually-active male, must agree to use a latex condom during any sexual contact with females of child bearing potential while participating in the study and for 3 months following last dose of TB-403.
11. For subjects on corticosteroids for endocrine deficiencies or tumor-associated symptoms, must be on a stable (or decreasing) dose for at least 7 days before first dose of study treatment.

Exclusion Criteria

1. Have any clinically significant disease considered by the investigator to interfere with study participation
2. Have not fully recovered from the acute toxic effects of prior anticancer therapy (e.g., chemotherapy, immunotherapy, radiation therapy) or are currently receiving cytotoxic chemotherapy, immunotherapy or radiation therapy. Subjects must be within the following timelines relative to first dose of study treatment:

* Myelosuppressive chemotherapy: Must not have received within 2 weeks (6 weeks if prior nitrosourea)
* Hematopoietic growth factors: At least 5 days since the completion of therapy with a growth factor
* Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the Sponsor
* Immunotherapy: At least 6 weeks since the completion of any type of immunotherapy, e.g., tumor vaccines
* Monoclonal antibodies: At least 7 days or 3 half-lives, whichever is longer, must have elapsed since prior treatment with a monoclonal antibody
* Radiotherapy: At least 14 days since the last treatment except for radiation delivered with palliative intent to a non-target site
* Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and ≥ 2 months must have elapsed since transplant
3. Have participated in another therapeutic clinical trial with an investigational drug within 1 month before first dose of study treatment
4. Have any known active uncontrolled infection
5. Have had major surgery or bone fracture within 28 days before first dose of study treatment
6. Have previously received TB-403
7. Have a history of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational drug
8. Are receiving increasing doses of corticosteroids
9. Are eligible for a curative treatment option
10. Have had a prior thrombotic event (e.g., pulmonary embolism, deep vein thrombosis) or are currently receiving therapeutic or prophylactic doses of anticoagulants.

Minimum Eligible Age

6 Months

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No